Ocugen (OCGN)

• Market cap: $266M
• 1 day: -3.19%
• 5 days: -2.38%
• 1 month: -4.57%
• 3 months: -24.49%
• 6 months: -46.25%
• Year to date: 38.94%
• 1 year: 131.90%
• 5 years: 107.66%
• 10 years: -92.22%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

78% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 18

49% more call options, than puts

Call options by funds: $855K | Put options by funds: $575K

43% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 23

14% more funds holding

Funds holding: 101 [Q2] → 115 (+14) [Q3]

1.26% more ownership

Funds ownership: 26.42% [Q2] → 27.68% (+1.26%) [Q3]

25% less capital invested

Capital invested by funds: $105M [Q2] → $79.1M (-$26.3M) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 338% upside
• Avg. target: $6.17 575% upside
• High target: $7 666% upside

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

Chardan Capital Daniil Gataulin 33% 1-year accuracy 4 / 12 met price target	557% upside $6	Buy Maintained	18 Nov 2024
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 34 / 115 met price target	666% upside $7	Buy Reiterated	14 Nov 2024
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 34 / 115 met price target	666% upside $7	Buy Reiterated	11 Nov 2024
Chardan Capital Daniil Gataulin 33% 1-year accuracy 4 / 12 met price target	557% upside $6	Buy Maintained	8 Nov 2024
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 34 / 115 met price target	666% upside $7	Buy Reiterated	23 Oct 2024